Background/Aims: Postherpetic neuralgia (PHN) can be refractory to both medical and minimally invasive treatments. Its complex pathophysiology explains the numerous neurosurgical procedures that have been implemented through the years. Our objective was to summarize all available neurosurgical strategies for the management of resistant PHN and evaluate their respective safety and efficacy outcomes. Methods: A comprehensive systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A total of 38 studies comprising 811 patients with refractory PHN were included. The safety and efficacy of the following procedures were investigated: spinal cord stimulation (SCS), dorsal root entry zone (DREZ) lesioning, intrathecal drug delivery, caudalis DREZ lesioning, dorsal root ganglion (DRG) radiofrequency lesioning, peripheral nerve stimulation, gamma knife surgery, deep brain stimulation, cordotomy, percutaneous radiofrequency rhizotomy and Gasserian ganglion stimulation. Conclusions: There are several available neurosurgical approaches for recalcitrant PHN including neuromodulatory and ablative procedures. It is suggested that patients with resistant PHN undergo minimally invasive procedures first, including SCS, peripheral nerve stimulation or DRG radiofrequency lesioning. More invasive procedures should be reserved for refractory cases. Comparative studies are needed in order to construct a PHN neurosurgical management algorithm.
Introduction
Postherpetic neuralgia (PHN) is a debilitating neuropathic pain syndrome which is characterized by pain persisting for more than 1-3 months at the site of acute zoster after the rash has healed [1, 2] . The incidence of PHN following acute zoster infection has been reported in the range of 10-20%, being severer and more prevalent in the elderly [3] [4] [5] . The pain in PHN is frequently severe enough to disrupt the quality of lives of otherwise healthy individuals.
PHN pain is frequently characterized by mechanical allodynia while decreased pinprick sensation and paresthesias are also common [2, 5] . The mechanisms implicated in the development of pain in PHN are complex and involve injury of the peripheral nerves and alterations in the central nervous system signal processing and central sensitization; however, the actual cause of PHN is not totally understood [6] . It has been hypothesized that dam-
Methods

Search Strategy and Selection Criteria
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [11] . Eligible articles were identified through searches of the PubMed and Cochrane databases up to October 2018 by two independent reviewers (P.T., M.S.T.). The following search algorithm was used: postherpetic neuralgia AND (cordotomy OR cingulotomy OR neurosurgery OR DBS OR deep brain stimulation OR intrathecal OR spinal cord stimulation OR rhizotomy OR motor cortex stimulation OR thalamus OR transcutaneous stimulation OR DREZ OR dorsal root entry zone lesioning OR dorsal root ganglion stimulation). A study was included in this systematic review if it fulfilled the following predefined criteria: (i) randomized controlled trials or prospective or retrospective observational analyses reporting on neurosurgical treatments of refractory PHN, (ii) studies published in English up to October 2018, (iii) studies reporting on pain reduction either with visual analog scale (VAS) scores before and after the procedure (continuous variable) or by using a pain reduction cutoff percentage (categorical variable). Excluded studies met at least one of the following criteria: (i) case reports, (ii) animal studies, (iii) reviews, meta-analyses, letters to the editor or editorials and (iv) studies reporting on patients who underwent 2 or more different neurosurgical procedures at the same time.
Data Extraction
Two reviewers (P.T., M.S.T.) independently reviewed the included studies and extracted data. All disagreements were resolved with consensus by the addition of a third reviewer (N.M.B.). Data extraction was based on a predefined Excel spreadsheet with the following variables: first author, year of publication, country and institution, years of enrollment, study design and study period, sample size, patient baseline demographics, number of patients who had antiviral therapy during the acute zoster infection and epidural block, medical or surgical treatments that had previously failed, days passed from the acute zoster to the neurosurgical treatment under investigation, affected dermatomes, VAS before and after the procedure, use of medication after the procedure, followup duration, procedure-related complications and additional procedures needed for pain management.
Risk of Bias Assessment
Risk of bias was assessed by two investigators (P.T., M.S.T.). Nonrandomized trials were evaluated according to the criteria proposed by the Cochrane tool for observational studies (ACRO-BAT) for the following domains: (i) confounding, (ii) selection, (iii) measurement of interventions, (iv) deviations from intended interventions, (v) missing data, (vi) measurement of outcomes and (vii) selection of the reported result. Studies were assessed as low, moderate or high risk of bias in every domain.
Statistical Synthesis and Analysis
Descriptive statistics were applied as appropriate. Categorical variables were summarized as frequencies and percentages and continuous variables as mean and standard deviations when available. For studies that reported continuous data as medians and range, the method proposed by Hozo et al. [12] was utilized to convert it to mean and standard deviation.
Results
Search Results
Literature search yielded 356 potentially relevant records after duplicates had been removed. After screening titles and abstracts, 55 articles were retrieved for full-text evaluation. Thirty-nine studies met the predetermined eligibility criteria and were included in the systematic review as shown in the PRISMA flow diagram (Fig. 1) . Table 1 presents important study and patient features. A detailed assessment of risk of bias is available in the online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000499476). Postoperative outcomes and baseline patient characteristics for the various neurosurgical approaches for the management of recalcitrant PHN are summarized below (Table 2) .
Spinal Cord Stimulation
Ten studies comprising 243 patients were identified (weighted mean age 58.9 years, 53.1% male) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 3 studies with available data, all patients were unsuccessfully treated with antiviral agents, epidural and/or nerve blocks and multiple pain medications including gabapentin, pregabalin, nonsteroidal anti-inflammatory drugs, opioids, antiepileptics and antidepressants [14, 16, 17] . The SCS was performed at the thoracic (81.7%), cervical (12.3%), lumbar (2%) and cervicomedullary junction (4%) levels after a mean of 17.6 months following zoster onset. Implantation of the SCS devices was performed in a 2-stage procedure only in patients who experienced a successful trial stimulation (86.5%). The mean VAS before and after the SCS was 7.6 and 2.7 after the long-term follow-up (18.2 months). Pain reduction > 50% was documented in 41.1% (88/214) of patients from 6 studies with relevant data. Interestingly, the pain-reducing effect of SCS was consistent both in studies with short-(less than a year) and long-term follow-up. There was a dramatic decrease in patients (94.7%, 18/19 patients) who required opioids following the SCS in the study by Harke et al. [21] . However, in another study, no change between the preand postprocedural analgesic medication dose was reported in the 21 patients who observed analgesic effects of the SCS [14] . No major complications were reported other than transient hypotension (3/14 patients), urinary retention (7/14 patients) and a snapped quadripolar lead where the procedure had to be repeated [14, 17] .
DREZ Lesioning
Six studies reporting on DREZ lesioning for the treatment of refractory PHN were identified, including 84 patients overall [23] [24] [25] [26] [27] [28] . The weighted mean age was 70 years (66.7% male) from studies with available data. The procedure was performed after a mean of 3.6 years following zoster onset at the thoracic (79.2%) and cervical 
IT Injections/Pumps with Analgesics
Five studies including 255 patients (weighted mean age 63.2 years, male 50.2%) were identified that implemented IT drug injections or pump insertions for resistant PHN [30] [31] [32] [33] [34] . All patients had used multiple pharmacological agents with very limited efficacy. The intervention was performed after a mean of 31.3 months from zoster onset. The mean patient-reported VAS scores were 7.3 and 4.6 before and after the procedure, respectively, while 41.8% of patients reported pain reduction > 50%. More specifically, 108 patients received IT injections of methylprednisolone and lidocaine, and 87% of them reported pain reduction > 50%. Of note, 1 study reported pain increase in all 6 patients who had the combined methylprednisolone and lidocaine IT injection [30] . On the other hand, only 8.5 and 6.2% of patients who received lidocaine and midazolam IT injections, respectively, reported pain reduction > 50% [30, 31, 34] . A very high percentage of patients who received midazolam reported side effects including sedation (85.4%), nausea and vomiting (6.2%) as well as headache (4.1%). Finally, only 1 small study of 4 patients inserted IT opioid pumps and reported a mean 41% pain reduction. However, 2 patients discontinued this therapy due to opioid-related side effects, depression and loss of efficacy.
Caudalis DREZ Lesioning/Nucleotomy
Five studies comprising 63 patients with resistant trigeminal PHN to medical therapy were identified from the literature review [23, [35] [36] [37] [38] . Four studies performed caudalis DREZ lesioning/stereotactic nucleotomy-nucleotractotomy using a radiofrequency generator, and 1 study performed ultrasonic destruction of the nucleus caudalis 4 months to 4.5 years following zoster onset. This strategy achieved a high percentage of pain-free patients [38] reported at least one of the following complications in all three patients (100%) including ipsilateral facial and contralateral arm and body sensory loss. Also, the study by Grigoryan et al. [35] which used ultrasonic nucleus caudalis destruction reported complications in 75% (3/4) of patients including contralateral body sensory loss, ataxia and Brown-Sequard syndrome. Chivukula et al. [23] reported one incidence of neuropathy/radiculopathy among the three patients who had caudalis DREZ lesioning.
DRG Pulsed Radiofrequency Lesioning
Two studies including 69 patients (mean weighted age 68 years, 47.8% male) with nonresponsive PHN to medical therapy were found [39, 40] . The average interval between zoster onset and the procedure was 21.9 months. Pulsed radiofrequency was performed in the thoracic, cervical and lumbar DRG in 69.6% (48/69), 20.3% (14/69) and 10.1% (7/69) of the patients. Patients had a mean pain score of 6.9 and after a mean follow-up of 3.5 months, it decreased to 2.7. No major complications were reported in the included studies suggesting the high safety profile of this procedure. One study reported a mean reduction of the morphine equivalent dose from 35.2 mg before to 20 mg after the procedure [40] . The study by Kim et al. [39] documented that 3/49 (6.1%) patients discontinued all analgesic medication while the rest reduced the dose or maintained it to the pre-procedural levels.
Peripheral Nerve Stimulation
Three studies fulfilled the eligibility criteria of this review [41] [42] [43] . Overall 10 patients (age 57.3 years, 50% male) who underwent peripheral nerve stimulation were identified. This procedure was performed > 6 months from zoster onset at the trigeminal nerve (60%, 6/10) or thoracic dermatome distribution (40%, 4/10) after multiple treatment failures. The mean VAS score before and after the procedure was 8.6 and 2, respectively, which was reported by 2 studies. All patients (100%) reported a successful trial (pain relief > 50%) during the first 2-14 days. After a mean follow-up of > 20 months from the permanent pulse generator implantation, 80% (8/10) of the patients reported a satisfactory reduction (> 50%) in their pre-procedural pain. No major complications were reported.
Gamma Knife Surgery
Two studies reporting on gamma knife surgery for refractory trigeminal PHN with 19 patients (age 71.1 years, male 47.3%) were identified [2, 44] . The study by Urgosík et al. [44] targeted the trigeminal root entry zone while the study by Keep et al. [2] targeted the retrogasserian trigeminal nerve and the centromedial thalamic nucleus at the same radiosurgical session. Nine patients (47.3%) reported pain relief > 40% during the 29.6-month interval [2, 44] . No complications from the radiosurgery were reported except for pain recurrence in 2 patients who initially demonstrated pain relief.
Other Approaches with Sparse Data
Several other neurosurgical procedures for resistant PHN have been published in single studies. A study of 3 PHN patients reported that DBS of the nucleus ventralis posterior lateralis resulted in 1 (33.3%) patient reporting successful DBS trial (> 50% pain relief) [45] . In this patient, DBS did not maintain the analgesic effect at the 6-month follow-up interval. Brown and Pilitsis [46] published the results of motor cortex stimulation in 2 patients with recalcitrant trigeminal PHN. Both patients reported a significant pain relief (VAS decreased from 10 to 2 and 5 to 0) lasting several months following the procedure.
Tomycz et al. [47] suggested that cordotomy may be used for several pain syndromes and included 1 patient with resistant PHN for 3 years. This patient had a much improved pain outcome during the 5-week follow-up, but suffered transient leg weakness. A peripheral nerve surgery approach involving excision of peripheral nerves causing the recognizable PHN pain and implantation directly to the muscle was suggested by a study of 3 patients [48] . The authors concluded that all 3 patients were painfree during the mean 10-month follow-up period, without any procedure-related complications. One of these patients discontinued all pain medication by 2 weeks postoperatively.
A study of 9 patients who underwent percutaneous radiofrequency rhizotomy for trigeminal PHN showed that 88.8% (8/9) of patients had pain relief [49] . However, during the mean 25.1-month follow-up interval, 3 patients needed an additional procedure. Taub et al. [50] performed Gasserian ganglion stimulation in 4 patients and found that only 1 (25%) elected to have a permanent implantation after the early 3-day trial. This patient did not achieve a sustainable pain relief (> 50%) during the chronic stimulation. Finally, 1 randomized trial was identified that implemented pulsed radiofrequency lesions to the intercostal nerve through a costal angle puncture [51] . This study showed that intercostal nerve radiofrequency lesions are associated with a higher pain-reducing effect and quality of life and lower use of tramadol compared to the sham group during the 6-month follow-up. However, the absolute reduction in VAS score was not provided for each group separately.
Summary of Findings
A total of 39 studies comprising 813 patients with refractory PHN were included. Ten studies with 243 patients reported use of SCS. The mean VAS score was 7.6 and 2.7 before and after the procedure. No serious complications were reported during the mean follow-up (18.2 months). DREZ lesioning was performed in 84 patients. The mean VAS score before and after the procedure was 8.7 and 3.7, respectively. One third of these patients reported a change in the character of pain from burning to aching/throbbing. During the postoperative period, 44.6% of patients developed motor deficits which were attributed to the procedure. Five studies investigated the effect of IT injections or pump insertions. The combined methylprednisolone and lidocaine IT injections demonstrated a very strong analgesic effect (87% of patients reported pain reduction > 50%); however, results were inconsistent between the included studies. Other medications used individually included lidocaine, midazolam and opioids with limited efficacy. Caudalis DREZ lesioning/nucleotomy was reported in 5 studies with a total of 63 patients. This strategy showed that 78.3% of patients were pain-free during the 35.8-month mean long-term follow-up. However, serious motor and sensory deficits occurred in 75-100% of patients in these studies. DRG pulsed radiofrequency lesioning was reported by 2 studies (69 patients) and was associated with a notable pain reduction (mean VAS before and after was 6.9 and 2.7, respectively) without any major complications during the mean 3.5 months of follow-up. Peripheral nerve simulation was reported by 3 studies comprising 10 patients in total. This strategy was among the safest and most effective, demonstrating a VAS pain reduction from 8.6 to 2 without any complications during the follow-up (> 20 months). Gamma knife surgery targeting the trigeminal nerve and/or centromedial nucleus was performed in 19 patients across 2 studies. No complications were reported, and 47.3% of patients reported pain relief > 40% during the mean 29.6-month interval.
Discussion
This was the first systematic literature review including all available neurosurgical approaches for the management of resistant PHN. In the current study we identified several different existing neurosurgical strategies, which are associated with various safety and efficacy profiles. SCS, DREZ lesioning and IT medication were the most frequently reported. Peripheral nerve stimulation, SCS and DRG pulsed radiofrequency lesioning achieved the highest pain reduction and were not associated with serious complications. Gamma knife surgery, spinal DREZ and caudalis DREZ lesioning/nucleotomy were efficacious but the latter two were associated with a high incidence of major postoperative complications.
The complex pathophysiology of PHN involving peripheral and central nervous system processes explains why there is a variety of potential pharmacological agents and surgical procedures [10] . Specifically, first-line therapies including topical lidocaine patches, and oral gabapentin, pregabalin and tricyclic antidepressants have been proven safe and effective with only minimal systemic side effects. In cases where the analgesic effect is unsatisfactory, capsaicin patches, oral opioids, epidural injections and nerve blocks have been used with a varying efficacy [52] . Notably, in some patients even multiple pharmacological therapies will be unsuccessful to manage the debilitating pain of PHN. These patients are potential candidates for one of the neurosurgical approaches that the current study describes [52] .
Moreover, DRG radiofrequency lesions seem to perform well without any associated complications; however, the mean follow-up of the studies was only 3.5 months which limited the capacity to detect chronic complications [39, 40] . Our results demonstrate that peripheral nerve stimulation and SCS achieved an average of 76.5 and 64.4% pain reduction; those two procedures are less invasive among neurosurgical options, show promising results and are generally safe. We believe that they should be considered as a reliable first choice when recalcitrant PHN cases fail all other noninvasive treatments. Unfortunately, no comparative studies were identified in the literature search which limits our capability to suggest superiority of the one over the other strategy. The authors' personal experience with SCS in PHN, while limited, has not mirrored the results reported in this review. SCS might fail in cases where the DRG cells are destroyed; importantly however, the use of preoperative somatosensory evoked potentials can successfully predict whether SCS will be effective or not [53] . Further prospective and comparative studies with long-term follow-up intervals are needed in order to validate our findings and provide new insights into the neurosurgical management of PHN.
IT medications have been offered to PHN patients by means of injections and implanted pumps. Two randomized trials have been published comparing IT injections of methylprednisolone plus lidocaine versus lidocaine alone with extremely opposite results [30, 34] . Kotani et al. [34] suggested that the combined methylprednisolone plus lidocaine outperformed the lidocaine alone injection; however, this trial's results have been questioned by several authors [52, 54] . The second trial by Rijsdijk et al. [30] found markedly different results despite the fact that the design differences were small except for slight modifications in the injected drug dosages; however, they could not identify the reason of their contradictory findings. Moreover, midazolam IT injections had a poor pain-reducing effect [31] . The only IT pump insertion study investigated the effect of opioid pumps in 4 patients, showing a promising short-term VAS score reduction; nevertheless, there are concerns in respect to the durability of its pain-alleviating effect and potentially intolerable opioid-related side effects [33] .
Several studies have examined the effect of more invasive neurosurgical procedures for PHN patients including DREZ lesioning in the spinal cord and caudalis DREZ/ spinal trigeminal nucleotomy. In light of the major complications and morbidity that both procedures can impose, the authors suggest that they are reserved for the most recalcitrant PHN cases. Nevertheless, it should be mentioned that the majority of major complications reported in patients who received DREZ lesioning in the spinal cord came from the study by Friedmann et al. [26] published in 1987. Another important point is that DREZ is generally effective for allodynia/hyperalgesia whereas the aching or deep pain are commonly unrelieved [29, 55] . Of note, DREZ lesioning is a more challenging procedure when performed in the thoracic spinal cord due to its anatomy (more white matter compared to cervical/ lumbar spinal cord). In theory, this can increase the risk of motor deficits for thoracic PHN cases. However, future comparative studies with long-term follow-up intervals would be needed to validate that. Furthermore, stereotactic radiosurgery might have a potential role in the management algorithm of PHN patients given that approximately 50% of the patients reported pain relief > 40% during an average 30-month follow-up interval. Importantly, patients who had gamma knife surgery did not report any major complication; nevertheless, these results stem from 2 retrospective studies including 19 patients only [2, 44] . Finally, only sparse data from single studies were identified regarding other neurosurgical strategies including motor cortex stimulation, DBS, cordotomy, percutaneous radiofrequency rhizotomy, Gasserian ganglion stimulation, radiofrequency intercostal nerve lesioning and peripheral nerve implantation in the muscle. There is an evident need of prospectively designed comparative studies in order to help guide patients who suffer recalcitrant PHN towards the most efficacious and safe procedures. These studies should specifically report the conditions in which each technique works or does not work.
Limitations
To our knowledge, this is the first systematic literature review summarizing all available neurosurgical procedures for the management of resistant PHN. However, a number of limitations should be noted. First, the nonrandomized nature of these studies limits the generalizability DOI: 10.1159/000499476 of our results. Second, several of our included studies were case series including a small number of patients. Also, different centers, surgeons and older studies create heterogeneity in the current study. Last, some studies reported the mean VAS score reduction, whereas others reported the percentage of patients who achieved > 50% pain reduction; when possible both outcomes were synthesized, and this has caused discrepancies in the reported efficacy of each procedure.
Conclusions
The available neurosurgical approaches for recalcitrant PHN mostly include neuromodulatory and ablative procedures. It is suggested that patients with resistant PHN undergo minimally invasive, reversible, neuromodulatory procedures first, including SCS and peripheral nerve stimulation which have demonstrated promising postoperative analgesia, albeit in studies without head-tohead comparison. DRG radiofrequency lesioning should also be considered after the failure of less invasive neuromodulatory approaches. More invasive and irreversible neurosurgical procedures should be reserved for refractory cases, with consideration toward notable postoperative morbidity. However, it should be emphasized that the comparative efficacy of these neurosurgical procedures is yet to be investigated due to the total absence of comparative studies.
